{"a":[{"_":"Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpoint","$":{"href":"/biotech/otsuka-heads-fda-ionis-partnered-als-drug-hits-primary-phase-3-endpoint","hreflang":"en"}}]}
Phase 3positivePositive
AI Analysis
Summary
Otsuka and Ionis Pharmaceuticals' phase 3 study of their ALS drug candidate met its primary endpoint, positioning the partners to pursue expedited regulatory approval discussions with the FDA.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Phase 3 study hit primary endpoint
Importance:8/10
Sentiment:
0.80
ALSPhase 3primary endpointFDApartnership
Read the original article
Published by FierceBiotech on September 22, 2026 9:23 AM